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Chemotherapeutic agents that target tubulin continue to be
important components of current cancer therapy. To date,
taxanes and vinca alkaloids have been the most clinically
important classes of tubulin-binding drugs. Both are natural
compounds that are highly effective in the treatment of a
number of cancers because of their ability to disrupt microtu-
bule dynamics by inducing a potent mitotic block and subse-
quent cell death.1 Nonetheless, certain cancers either do not
respond to treatment or develop resistance, which poses a
major clinical problem for the use of these agents.
Considerable effort has been directed towards isolating and
synthesising new antimitotic agents that target the microtu-
bule system and display efficacy against drug-refractory carci-
nomas. Newly described compounds include natural products
(e.g., dolastatin, discodermolide and epothilones), derivatives
and structural analogues of traditional antimitotic agents,
and novel synthetic molecules.
Recent research has also been directed towards decipher-
ing the mechanisms by which cancer cells resist the effects
of tubulin-targeted drugs, including alterations in the drug
target (e.g., tubulin mutations), tubulin isotype expression
and microtubule dynamics, and also modifications in micro-er Ltd. All rights reserved
.
u.tubule-regulatory proteins; thus, providing additional oppor-
tunities for the development of novel therapies. This article
describes the tubulin/microtubule system, with specific
emphasis on mechanisms mediating resistance, and reviews
strategies for enhancing the efficacy of microtubule-targeted
cytotoxic therapy.
2. Tubulin and the microtubule system
Microtubules are composed of repeating a/b-tubulin heterodi-
mers that self-associate into polymers.2 Tubulin exists in dif-
ferent isotypic forms, and multiple isotypes (7a-tubulin and
7b-tubulin isotypes) with tissue-specific expression have been
identified in human cells.3 The various b-tubulin isotypes are
evolutionarily conserved across species and differ from each
other predominantly in their carboxy terminal region.2 This
region binds distinct microtubule-associated proteins (MAPs)
and is therefore thought to influence microtubule stability
and functionality. Tubulin isotype composition appears to
be important for the cellular response to tubulin-targeting
anticancer drugs.2,3
Microtubules are highly dynamic structures that play an
integral role in cellular growth, vesicular transport and
mitosis.2 The ability of microtubules to polymerise and.
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during mitosis.3 In an interphase cell, microtubules originate
from the centrosome forming a hub and spoke-type network
and are responsible for transporting substances around the
cell. During cell division, this network is completely disassem-
bled and reformed into mitotic spindles, across which dupli-
cate sets of chromosomes line up and are divided equally
into two daughter cells. Upon completion of mitosis, the spin-
dle disassembles and the interphase microtubule network re-
forms. Factors that disrupt this process or affect microtubule
dynamics will induce mitotic arrest and kill the cell. Not sur-
prisingly, the tubulin/microtubule system is an important tar-
get for anticancer drug design.1
3. Effects of tubulin-binding drugs on
microtubule structure and dynamics
Under normal circumstances, tubulin dimers and the micro-
tubule polymer exist in a state of dynamic equilibrium within
the cell (Fig. 1).1 The addition of a destabilising agent, such as
a vinca alkaloid (e.g., vincristine or vinblastine), at high con-
centrations (i.e., excess drug per tubulin molecule) pushes
the equilibrium towards the tubulin dimers, resulting in dis-
ruption of the microtubule architecture. By contrast, the addi-
tion of a microtubule-stabilising agent, such as a taxane
(paclitaxel or docetaxel), at high cellular concentrations en-
hances tubulin polymerisation, resulting in an increase in
polymer mass and the formation of microtubule bundles.1
Although vinca alkaloids and taxanes disrupt cells in dif-
ferent ways, both classes of drugs bind to b-tubulin, either
predominantly to the tubulin dimer (in the case of vinca alka-
loids) or primarily to the microtubule polymer itself (in the
case of taxanes).1Fig. 1 – Microtubule stability reflects a dynamic equilibrium betw
agents such as the taxanes move the equilibrium towards the po
alkaloids move it in the opposite direction. Reproduced, with p
Bentham Science Publishers Ltd).In drug-sensitive cells, tubulin-targeting agents are
thought to disrupt microtubule dynamics by interfering with
mitotic spindle function, inhibiting cell proliferation at the
metaphase/anaphase junction of mitosis (Fig. 2).4,5 Disrup-
tion of microtubule dynamics results in the failure of bipo-
lar spindle attachment to the kinetochores of metaphase
chromosomes.6 This engages the spindle assembly check-
point, which prevents the metaphase-to-anaphase transi-
tion.6 Tumour cells then undergo cell-cycle arrest during
the G2/M phase of the cell cycle, followed by apoptotic cell
death.7 By contrast, resistance to tubulin-targeting drugs
can result in cell survival and multiplication.8 Mechanisms
responsible for drug resistance are multifaceted and include
those associated with the multidrug-resistance (MDR) phe-
notype and alterations in the microtubule and associated
proteins.
Strategies to increase the effectiveness of antimicrotubule
cytotoxic therapy in the management of cancer include the
development of novel agents, the application of changes in
tumour sensitivity following microtubule alteration to make
treatment with existing agents more effective, and the down-
regulation of specific b-tubulin subclasses or of regulators of
microtubule function.
4. Novel antimicrotubule drugs
Several novel antimitotic agents have been identified and are
being evaluated in clinical trials (Table 1). Dolastatin, crypto-
phycins and curacin A are microtubule-destabilising agents,
whereas discodermolide and epothilones stabilise microtu-
bules.8 Both discodermolide and the epothilones are of partic-
ular interest in novel drug development because they inhibit
growth of MDR cell lines.9een tubulin dimers and the microtubule polymer. Stabilising
lymerised state, while destabilising agents such as the vinca
ermission, from Ref. [1] (reproduced with permission from
Table 1 – Novel microtubule-targeted agents currently under evaluationa
Compound/substrate Origin Competes MDR
Discodermolide Sponge Taxanes Low
Epothilones
Ixabepilone Myxobacterium Taxanes Low
Dolastatin
Dolastatin-10 Marine mollusk Vinca alkaloids High
TXT-1027
Cryptophycins
Cryptophycin 52 and 55 Cyanobacterium Vinca alkaloids Low
Curacin A Cyanobacterium Colchicine NA
MDR, multidrug resistance; NA, not applicable.
a Derivatives and structural analogues of vinca alkaloids and taxanes have displayed less cross-resistance to the MDR phenotype.
Fig. 2 – Effects of tubulin-targeting drugs on cancer cells.
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Dolastatin-10 is a novel pentapeptide that inhibits microtu-
bule assembly and tubulin polymerisation. In phase II studies,
dolastatin-10 lacked significant clinical activity when used as
a single agent in the treatment of hormone-refractory pros-
tate cancer,10 advanced breast cancer,11 advanced pancreati-
cobiliary cancers12 and treatment-naive patients with
advanced melanoma.13 Newly identified derivatives of dolast-
atin-10 have shown superior activity in vitro and in vivo in
preclinical trials14,15 and are currently being tested in phase
I trials.16,17
4.2. Cryptophycins
Cryptophycins are active in breast and ovarian tumour cells
that overexpress P glycoprotein and have shown promise in
combination therapy with 5-fluorouracil, doxorubicin, paclit-axel and irinotecan.18–20 Cryptophycin 52 is currently in early
clinical development for the treatment of solid tumours.
4.3. Curacin A
Curacin A is a potent competitive inhibitor of colchicine bind-
ing to tubulin and causes a high level of growth inhibition in
cancer cell lines. However, the low water solubility and lack of
chemical stability of curacin A are significant detriments to its
clinical development.21
4.4. Discodermolide
Discodermolide stabilises microtubules, inducing cell-cycle
arrest during the G2/M phase of the cell cycle. In vivo, it af-
fects microtubule assembly more rapidly than paclitaxel.9 It
is significantly cytotoxic in P-glycoprotein-expressing cells,
although not to the extent of epothilones.9,22 Discodermolide
6 E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 3 –9acts synergistically with paclitaxel and, unlike epothilones, it
cannot be substituted for paclitaxel in a paclitaxel-dependent
cell line.22 Limited natural supplies have hampered in vivo
studies, although large-scale synthesis has recently been
achieved and the synthetic material is now undergoing phase
I clinical trials for use in the treatment of pancreatic cancer.23
4.5. Epothilones
Epothilones were the first novel structural class of com-
pounds found to have a taxane-like mechanism of action,24
and they are the best studied of the new antimicrotubule
agents. Data from structure–activity relationship studies sug-
gest a common pharmacophore for binding of epothilones
and taxanes.25,26 Epothilones are competitive inhibitors of
[3H]-paclitaxel binding to microtubule polymers.24,26,27 These
data, combined with those from mutational and pharmaco-
phore analyses, suggested an overlapping of binding sites
for epothilones and paclitaxel.26,28,29 Although it now appears
that paclitaxel and epothilone do not have a common phar-
macophore and that each ligand binds to the tubulin-binding
pocket in a unique way.30 Importantly, unlike paclitaxel, epo-
thilones are not transported by P glycoprotein, thus, they
retain their potency in MDR cell lines. Furthermore, epothil-
ones have excellent cytotoxicity profiles in several paclit-
axel-resistant cell lines containing b-tubulin mutations.28
Epothilone analogues have shown efficacy against a range
of tumour types, and a semi-synthetic analogue of epothilone
B, ixabepilone [BMS-247550], is currently undergoing phase
II/III clinical trials.31
Data on ixabepilone have been promising so far. In a clin-
ical trial in 37 patients with metastatic or locally advanced
breast cancer in whom neoadjuvant or adjuvant therapy with
a taxane had previously failed, treatment with ixabepilone re-Fig. 3 – The mechanisms mediating resistance to antimicrotubul
relating to the drug target. Reproduced, with permission, from
Publishers Ltd).sulted in complete remission in 1 patient, partial remission in
7 patients and stable disease in 13 patients.31
5. Antimicrotubule alterations associated
with antimicrotubule resistance
Despite the promise of novel tubulin-binding agents in the
treatment of taxane-refractory tumours, there are probably
some overlapping mechanisms of drug resistance, and a bet-
ter understanding of what causes such resistance is needed if
therapy is to be improved. Determining the mechanisms that
mediate drug resistance has become an important area of re-
search.1 Several mechanisms may be involved in mediating
resistance to antimicrotubule drugs, including drug efflux
and processes that resist apoptosis. In this review, however,
the focus is onmechanisms affecting the target of such drugs,
namely tubulin mutations and altered expression of b-tubulin
isotypes and microtubule-regulatory proteins (Fig. 3).1
5.1. Tubulin mutations
Mutations in the cellular target of tubulin-binding agents (i.e.,
the b-tubulin subunit) account for some of the observed resis-
tance to these agents.32 Several b-tubulin mutations have
been identified using antimicrotubule-resistant cell lines (re-
viewed by Drukman and Kavallaris32). These mutations have
varied effects on drug binding and microtubule stability.32,33
The consequences of tubulin mutations have been investi-
gated by selecting for resistance-conferring mutations in lym-
phoblastic leukaemia cell lines through exposure to
escalating concentrations of desoxyepothilone B (dEpoB), an
epothilone analogue.34 This resulted in mutations that push
the microtubule equilibrium towards less-stable microtu-
bules, making it more difficult for a microtubule-stabilisinge agents include drug efflux and anti-apoptosis as well those
Ref. [1] (reproduced with permission from Bentham Science
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lines that were hypersensitive to vinblastine, a destabilising
agent, suggesting that an understanding of how the stability
of the microtubules affects drug action could potentially di-
rect therapy to patients who are more likely to respond.
5.2. Changes in the expression of b-tubulin isotypes
An increasing body of evidence suggests that the expression
of specific b-tubulin isotypes is altered in cells that are resis-
tant to antimicrotubule agents.3,32,33 In particular, several
studies have shown that poor response to taxane treat-
ment is associated with increased expression of class III
b-tubulin.35–38
In the first study that reported an association between b-
tubulin isotype gene expression and taxane-resistant patient
tumours, classes III and IVa b-tubulin were significantly in-
creased in clinically derived paclitaxel-resistant ovarian epi-
thelial tumour cells compared with untreated primary
tumours.35
In subsequent research, Rosell et al.36 showed that pa-
tients with non-small-cell lung cancer tumours expressing
higher intrinsic levels of class III b-tubulin had shorter sur-
vival times when treated with paclitaxel and carboplatin ther-
apy than those with tumours expressing low b-tubulin levels.
In addition, increased expression of class III b-tubulin was
associated with docetaxel resistance in human breast
cancer.38
Downregulating class III tubulin expression has also been
investigated as away to restore taxane sensitivity in lung can-
cer cell lines.39 In the first study of its type, paclitaxel-resis-
tant lung cancer cells that displayed a 4-fold increase in Hb4
expression compared with parental cells were treated with
antisense phosphorothioate oligodeoxynucleotides. Results
showed a concentration-dependent reduction in Hb4 mRNA
expression. Immunofluorescence staining showed a decrease
in class III protein expression that corresponded to a signifi-
cant increase in sensitivity to paclitaxel.39 These results could
be potentially clinically relevant if manipulation of the
expression of specific b-tubulin isotypes and sensitisation of
cancer cells to antimitotic agents, particularly stabilising
agents, become possible. Future research might also enable
the identification of small molecule inhibitors of these spe-
cific isotypes, which may be useful in combination therapies.
In contrast to changes in isotype expression, mutations in
b-tubulin have not yet been associated with antimicrotubule
drug resistance in ovarian, breast or lung cancer. It will be
interesting to see how epothilones and their analogues pro-
gress in this regard and whether patients develop resistance
and if so whether this is mediated by mutations in b-tubulin.
Although mutations and mutational studies have been valu-
able in providing a better understanding of how drugs target
the b-tubulin molecules, they do not appear to be relevant
in terms of clinical studies.
5.3. Altered expression of microtubule-regulatory proteins
MAPs are important structural and regulatory components of
microtubules. On the one hand, alterations in their expres-
sion can affect microtubule function and have been associ-ated with resistance to antimicrotubule drugs. On the other
hand, by manipulating the expression of microtubule pro-
teins it is possible to enhance the action of antimicrotubule
drugs. Increased expression of MAP4 for example has been
associated with an increase in polymerised molecules, en-
hanced binding of paclitaxel, increased sensitivity to paclit-
axel, and increased resistance to microtubule-destabilising
agents.40,41 By contrast, depletion of MAP4 has been associ-
ated with decreased polymeric tubulin.42
Regulation of MAP4 through p53 transcriptional status has
been shown to determine sensitivity to antimicrotubule
drugs.40 When p53 is inactive, increased MAP4 expression in-
creases microtubule polymerisation and facilitates paclitaxel
binding, which increases sensitivity to paclitaxel and de-
creases sensitivity to vinca alkaloids. Therefore, the action
of antimicrotubule drugs could be enhanced by controlling
p53-dependent regulation of MAP4. Indeed, such regulation
has been investigated in a preliminary trial in which doxoru-
bicin was used to induce p53 to repress MAP4, which was
then followed by sequential treatment with vinorelbine.43
Partial response was observed in 7 out of 16 patients and
the therapeutic regimen was well tolerated.
Another example of how the action of antimicrotubule
drugs can be enhanced through the manipulation of
microtubule-regulatory proteins involves stathmin, a major
tubulin-regulatory protein that is highly overexpressed in leu-
kaemia.44,45 Overexpression of stathmin has been associated
with decreased microtubule polymerisation and reduced pac-
litaxel sensitivity.46 Downregulation of stathmin has been
shown to sensitise K562 leukaemia cells to paclitaxel, resulting
ina synergistic inhibitionof growthandclonogenicpotential.47
This indicated that the efficacy of antimicrotubule drugs may
be enhanced by manipulating the expression of microtubule
proteins and that identifying differential expression of pro-
teins may predict treatment response.1
6. Conclusions
The tubulin/microtubule system remains an important target
for anticancer therapies, although acquired and intrinsic
resistance to antimicrotubule agents still poses a significant
clinical problem. Several strategies exist to overcome this
challenge and maintain the clinical importance of cytotoxic
therapy targeted at the microtubule. New antimicrotubule
agents are being developed that inhibit the growth of tumours
refractory to vinca alkaloids and taxanes.
In addition, improving the current understanding of how
aberrant expression of specific b-tubulin isotypes affects the
action of antimicrotubule drugs could potentially improve
therapeutic approaches (e.g., investigating the downregula-
tion of class III b-tubulin as a means of increasing sensitivity
to microtubule-stabilising agents). Microtubule changes that
affect stability may also be exploited to improve treatment re-
sponse (e.g., cells expressing less-stable microtubules are
hypersensitive to microtubule-destabilising agents). Other
potential strategies for overcoming resistance include gene
silencing or small molecule approaches that target-specific
regulators of microtubule function (e.g., downregulating
stathmin to increase the sensitivity of leukaemia to microtu-
bule-stabilising drugs).
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